

Bavarian Nordic is One of the Largest Pure-Play Vaccine Companies Globally

Bavarian Nordic is a fully integrated vaccine company focused on the research and development, manufacturing, and commercialization of life-saving vaccines.


We are a global leader in smallpox and mpox vaccines, which have been developed through our long-standing

partnership with the United States (US) government to enhance public health preparedness, and have a strong portfolio of vaccines for travelers and endemic diseases. Our manufacturing sites and network of manufacturing partners provide both reliability and flexibility as a vaccine supplier.

Our Global Presence in 2025

Founded in 1994 as a collaboration between Danish investors and German scientists, we have expanded our presence and operations globally.

- Our offices
- Our markets



- USA**
Clinical development, regulatory and commercial functions
- Switzerland**
Manufacturing, global marketing and sales functions
- Germany**
Research and development, sales, and commercial functions
- Denmark**
Headquarters, manufacturing
- Other countries**
Commercial and administrative functions: Belgium, Canada, France, Italy, Portugal, Spain, Sweden and United Kingdom

We are a pioneering force in vaccines — expanding our reach and impact through life-changing solutions. Protecting lives every day is an essential part of our DNA at Bavarian Nordic, and we aspire to develop vaccines that address unmet medical needs for the greater good of global society.

Committed to Helping Save and Improve Lives



Pioneering Research & Development

Strong heritage in vaccine development and cutting-edge technology drives our innovation to fight existing and emerging diseases



Expertise in Vaccine Manufacturing

Expertise in vaccine manufacturing and fill-and-finish capabilities enables our end-to-end commercial-scale manufacturing



Commercial Excellence

Established commercial infrastructure with presence in key US and EU markets drives profitable growth of our expanding vaccine portfolio

At a Glance

Founded: **1994**

CEO: **Paul Chaplin**

Global Headquarters: **Hellerup, Denmark**

Market Capitalization: **~USD \$2.17B** (as of December 2024)

US Headquarters: **Durham, North Carolina**

Market Trading: Nasdaq Copenhagen (OMX): **BAVA**

Revenue (FY 2024): **\$828M USD**

Level 1 ADR program in the US: **BVNR**


2024 Highlights

2.5 million+ vaccine doses were delivered to more than 75 countries in 2024

Private market launch of mpox vaccine in the US and Germany


Successful regulatory submissions for chikungunya vaccine in the US and Europe with commercial launch in 2025

A Strong Heritage in Vaccine Development



We have established a diverse portfolio of in-house developed and acquired products addressing infectious diseases across the globe. Our commercial vaccines are available in more than 30 countries, and through our partnerships with governments and international organizations, we are working to increase the availability of important vaccines to improve public preparedness in even more countries.


Our Evolving US Vaccines Portfolio Addresses Global Health Risks & Unmet Needs



JYNNEOS®
(Smallpox and Mpox Vaccine, Live, Non-replicating)

JYNNEOS®
(Smallpox & Mpox Vaccine, Live, Non-replicating)


JYNNEOS is approved for the prevention of smallpox and mpox disease in adults 18 years of age and older determined to be at high risk for smallpox or mpox infection.



RabAvert®
Rabies Vaccine

RabAvert®
(Rabies Vaccine)


RabAvert is indicated for pre-exposure vaccination, in both primary series and booster dose, and for post-exposure prophylaxis against rabies in all age groups.



Vaxchora®
(Cholera Vaccine, Live, Oral)

VAXCHORA®
(Cholera Vaccine, Live, Oral)


VAXCHORA is a vaccine indicated for active immunization against disease caused by *Vibrio cholerae* serogroup O1 in persons 2 through 64 years of age traveling to cholera-affected areas.



Vimkunya™
(Chikungunya Vaccine, Recombinant)

VIMKUNYA™
(Chikungunya Vaccine, Recombinant)

VIMKUNYA is a vaccine indicated for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 12 years of age and older.



Vivotif®
(Typhoid Vaccine Live Oral Ty21a)

VIVOTIF®
(Typhoid Vaccine Live Oral Ty21a)

VIVOTIF is indicated for the immunization of adults and children greater than 6 years of age against disease caused by *Salmonella typhi*.

Please see full Prescribing Information for [JYNNEOS](#), [RabAvert](#), [VAXCHORA](#), [VIMKUNYA](#), and [VIVOTIF](#).

Our Global Product Portfolio

We are a leading supplier of travel vaccines and a preferred partner with governments on vaccines for public preparedness.

Public Preparedness:

JYNNEOS®
(Smallpox and Mpox Vaccine, Live, Non-replicating)

Marketed as Imvamune® and/or Imvanex® outside the US

Our Pipeline:

Lyme disease Phase 1 planned in 2026

Epstein-Barr (EBV) Phase 1 planned in 2026

Travel Health:

RabAvert®
Rabies Vaccine

(Marketed as Rabipur® outside the US)

Vivotif®
(Typhoid Vaccine Live Oral Ty21a)

Vaxchora®
(Cholera Vaccine, Live, Oral)

Vimkunya™
(Chikungunya Vaccine, Recombinant)